Award for malaria vaccine developer

A developer who is in the progress of creating a new vaccine that could be used to tackle malaria around the world has been given a prestigious award.

Sanaria was named the best early-stage vaccine biotech at the Vaccine Industry Excellence Awards.

Live, attenuated parasites are used in the firm's vaccine, which is currently undergoing clinical testing to check its safety for humans.

Stephen L Hoffman, Sanaria's founder and chief executive, said: "This award caps a remarkable period of rapid progress and success in translating Sanaria's whole-organism, sporozoite malaria vaccine candidate from development through cGMP manufacturing and the initiation of clinical trials.

"It recognises the remarkable achievements and dedication of the entire Sanaria team and our collaborators."

The ceremony was held during the World Vaccine Congress in Washington, which also honoured other high-achievers in the health industry.

These included GlaxoSmithKline Biologicals for best vaccine R&D pipeline and Merck for best prophylactic vaccine.

News brought to you by Global Health TV, connecting health communities